Navigation Links
Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
Date:11/26/2008

BETHESDA, Md., Nov. 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and Chief Executive Officer, Dr. Christian Itin, will present at the Piper Jaffray 20th Annual Health Care Conference at the New York Palace Hotel on Wednesday, December 3, 2008. A simultaneous webcast of the presentation will be available on the company's website at www.micromet-inc.com.


    Forum:      The Piper Jaffray 20th Annual Health Care Conference
    Date:       Wednesday, December 3, 2008
    Time:       1:30 pm, Eastern Time
    Place:      The New York Palace
                455 Madison Avenue
                New York, NY 10022
    Webcast:    www.micromet-inc.com

In addition, Dr. Itin will participate in a panel discussion titled "Novel Antibody Technologies," which will be held at the conference on the same day from 12:00 noon until 1:00 pm, eastern time.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
4. Micromet, Inc. Reports First Quarter 2008 Financial Results
5. Micromet, Inc. Reports Second Quarter 2008 Financial Results
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Renal Disease Treatments: Products and T...824/Renal-Disease-Treatments-Products-and-Therapie...ducts and services, providing data for 2008 and es...nd compound annual growth rates (CAGRs) from 2009 ...
(Date:12/2/2009)...wire-USNewswire/ -- In response to a press confer... ," an initiative from the U.S. Anti-Doping Agenc... Responsible Nutrition (CRN), the leading trade as...stry, issued the following statement: ,, Stat..., "We share the concerns of Travis Tygart (USADA...
(Date:12/2/2009)...e-USNewswire/ -- ,, Statement by John Gay, Exe...ion ,, In response to a new campaign launched...ducate consumers and rid the marketplace of "rogue...s, the Natural Products Association, the oldest an... and manufacturers of dietary supplements and othe...
(Date:12/2/2009)...0 minutes of hospital arrival, study finds , ...ionwide program to get faster treatment for people...matically reduced the time between hospital arriva...-quarters of people with STEMI heart attacks -- so...hat shows major blockage of a heart artery -- were...
(Date:12/2/2009)...lic syndrome, study finds , , WEDNESDAY,...nough to keep overweight college football players ...that can lead to heart disease, a new study sugges... colleges and found that two-thirds were obese. Of... of conditions that raise the risk for heart disea...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 2Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 3Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 4Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 5Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 6Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 7Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 8Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 9Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 10Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Natural Products Association Issues Statement on New Supplement Safety Campaign 2Health News:Heart Attack Treatment Speeds Up Nationwide 2Health News:Heart Attack Treatment Speeds Up Nationwide 3Health News:Oversized College Football Players May Face Heart Risks 2
...ers in China who perceive themselves as being fat,...igher risk of developing depression and school-rel...searchers. This could be due to an inclination to ... seven different Chinese studies. Teenage girls wh...
...chers at The University of Texas M. D. Anderson Ca...ow-risk prostate cancer patients who are eligible ...l chemotherapy treatments. "With the advent of...ivity of the test, clinically insignificant tumors...
...octors believe that enforced bicycle helmet laws i...set this view aside.// Several studies sugge...ewer head injuries than non-wearers. But Dorothy R...prove public health. She reviewed data from ...
...mithKline said that the Food and Drug Administrati... 4 to 11//. Flovent HFA is a reformulation of...ly hydrofluoroalkane instead of chlorofluorocarbon... The medication initially was approved by the FDA...
...cidence of HIV/AIDS in the Indian armed forces is ...verage and efforts are being made to reduce// this...sday. "Contracting HIV/AIDS is not a crime. ... The national average of the incidence of HIV/AI...
... minorities may have particular problems with alco...or psychiatrist. He believes that these hidden pop...e the problem. In the United Kingdom, severa...and Maudsley NHS Trust. For example, 34% of ...
Other Medicine News:Health News:Obese Chinese Teens Low On Self-Esteem 2Health News:Can Enforcing Bicycle Helmet Laws Avoid Head Injuries? 2Health News:Incidence Of HIV/AIDS In The Indian Armed Forces Negligible 2
(Date:12/3/2009)...and BANGALORE, India, December 3 A...product and application,development services, toda...ft BioIT Alliance to extend its services focus int...rapidly evolving industry to leverage Aditi,s,supe...wledge and best,practices know-how. , Thi...
(Date:12/3/2009)...I, December 3 After two decades of...eir field, Lightlake Therapeutics, experts,have be... gene testing,subjects for a trial of a simple, sa...th Organisation has described as a global epidemic...se II trial for the everyday treatment against obe...
(Date:12/2/2009)... 2 Reportlinker.com announces that...catalogue: ,, Arthroscopes - A World Market Re...Arthroscopes---A-World-Market-Review.html ,, ...to their mounting scope and usage in the diagnosis... apart from knees. The number of arthroscopic shou...
Breaking Medicine Technology:Aditi Technologies Join Hands With Microsoft BioIT Alliance to Offer Solutions in Bioinformatics Space 2Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 2Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 3Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 4Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 5Reportlinker Adds Arthroscopes - A World Market Review 2Reportlinker Adds Arthroscopes - A World Market Review 3Reportlinker Adds Arthroscopes - A World Market Review 4Reportlinker Adds Arthroscopes - A World Market Review 5Reportlinker Adds Arthroscopes - A World Market Review 6Growth in German children 8924 1VA Reopening Health Care Enrollment to Thousands of Veterans 49475 1VA Reopening Health Care Enrollment to Thousands of Veterans 49475 2Sinovac Receives Chinas First Influenza A 28H1N1 29 Vaccine Order 12708 1Sinovac Receives Chinas First Influenza A 28H1N1 29 Vaccine Order 12708 2Sinovac Receives Chinas First Influenza A 28H1N1 29 Vaccine Order 12708 3
... MEETING, Pa., Oct. 6 Genaera,Corporation (Nasdaq...e 1,clinical trial of trodusquemine (MSI-1436), Ge...ype 2 diabetes and obesity. MSI-1436 is a novel,in...t controls the function,of both the leptin and ins...petite. In the study, MSI-1436 was found to be wel...
... Procedure May Eliminate 6 Weeks of Radiation Ther...t over the Internet Wednesday, October 22, 2008,...plorehealth , HAMPTON, Va., Oct. 6 /PRNewswire/ -...was diagnosed with breast cancer in May. Would she...about radiation or chemotherapy?, , To view the M...
Other Medicine Technology:Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial 2
Genu-Ranger® Hinged Range of Motion Knee Brace
GenuTrain
Ezy Wrap® Economy Knee Immobilizer
...justable Post-Operative Pin Knee Brace (POP) for p...n associated with ACL, PCL, MCL, and LCL surgeries... extension in 7 increments. Can be locked at full ...ompliance. Breakaway hinge bar converts long brace...
Medicine Products: